ARTICLE | Clinical News
Sustained Release Travoprost: Phase IIb started
December 15, 2014 8:00 AM UTC
Ocular Therapeutix began a double-blind, U.S. Phase IIb trial to compare a single dose of 0.36 mg Sustained Release Travoprost vs. twice-daily timolol eye drops in about 80 patients. ...